Reaktionsgleichung
Cl[C:2]1[C:3]2[CH:10]=[C:9]([C:11]([O:13][CH2:14][CH3:15])=[O:12])[NH:8][C:4]=2[N:5]=[CH:6][N:7]=1.[NH2:16][C:17]1[C:26]([O:27][CH3:28])=[CH:25][C:20]2[NH:21][C:22](=[O:24])[S:23][C:19]=2[CH:18]=1>>[CH3:28][O:27][C:26]1[C:17]([NH:16][C:2]2[C:3]3[CH:10]=[C:9]([C:11]([O:13][CH2:14][CH3:15])=[O:12])[NH:8][C:4]=3[N:5]=[CH:6][N:7]=2)=[CH:18][C:19]2[S:23][C:22](=[O:24])[NH:21][C:20]=2[CH:25]=1Komponenten
3
Versuchsvorschrift
75 mg (332 μmol) ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate (CAS-No: 187725-00-4) were transformed in analogy to example 1 using 6-amino-5-methoxy-1,3-benzothiazol-2(3H)-one to give after working up and purification 20.0 mg (15%) of the title compound.
Aufarbeitung
- customto give
- custompurification 20.0 mg (15%) of the title compound
Quellen und Nachweise
- ORD-Eintrag
- ord-63520f616092494cb8a169fe16399d56
- Quelldatensatz
- uspto-grants-2016_07
- Patentnummer
- US09382255B2
Verknüpfte Notizen
Wird geladen…